My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

177.20 +0.74 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Wall Street Holds Its Breath: Awaiting Powell's Verdict Amidst Pervasive Caution
Wall Street is currently gripped by a palpable "wait-and-see" sentiment, as investors adopt an overwhelmingly cautious stance ahead of Federal Reserve Chair Jerome Powell's highly anticipated speech at... 
Via MarketMinute
Topics Economy Stocks
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Economic Barometer: Consumer Spending and Labor Market Trends Under Scrutiny
The global financial landscape is currently navigating a period of heightened uncertainty, with key economic indicators signaling a notable deceleration in private consumption and emerging fragilities... 
Via MarketMinute
Topics Economy World Trade
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
These companies have successfully navigated similar obstacles before. 
Via The Motley Fool
Topics Intellectual Property
These Are the 3 Smartest Dividend Stocks Today
These three dividend stocks offer steady income and a history of delivering through thick and thin. 
Via The Motley Fool
Topics Economy
Federal Reserve Rate Cut Hopes Dwindle as Stubborn Inflation Surges Post-PPI
Washington D.C. – Hopes for an imminent Federal Reserve interest rate cut have significantly dimmed following the release of hotter-than-expected Producer Price Index (PPI) data on August 14, 2025. The... 
Via MarketMinute
Topics Bonds Economy Stocks
Sector Rotation in Full Swing: Cyclical Stocks Gain Favor as Investors Shift from Tech
The financial markets are currently experiencing a significant sector rotation, as investors increasingly shift their capital from growth-oriented technology stocks towards more value-driven cyclical... 
Via MarketMinute
Topics Economy
Treasury Yields and Dollar Climb as Inflation Report Shifts Market Dynamics
The financial markets are once again grappling with the persistent specter of inflation, as the latest reports have sent ripples through the bond market and currency exchange rates. Following a series... 
Via MarketMinute
Topics Bonds Credit Cards Economy
U.S. Economy Shows Resilience with Q2 GDP Growth, But Labor Market Cools
The United States economy presented a complex and somewhat contradictory picture in the second quarter of 2025, demonstrating a robust 3.0% annualized Gross Domestic Product (GDP) growth, a significant... 
Via MarketMinute
Topics Economy Supply Chain Workforce
Palantir Is Now the 19th Largest Public Company. Is This House of Cards About to Come Crashing Down?
Palantir Technologies is priced for perfection. Unfortunately, no situation on Wall Street is ever perfect. 
Via The Motley Fool
Topics Artificial Intelligence
Fed Watch: September Rate Cut Now 96% Likely After Favorable Inflation Data
The financial markets are abuzz with heightened expectations for a Federal Reserve interest rate cut in September, with probabilities soaring to an overwhelming 96%. This dramatic shift in sentiment... 
Via MarketMinute
Topics Bonds Credit Cards Economy
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive. 
Via The Motley Fool
Topics Retirement
Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
Via The Motley Fool
Topics Regulatory Compliance
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners. 
Via The Motley Fool
The Specter of Stagflation: Trump's Tariffs Cast a Long Shadow Over the U.S. Economy
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic... 
Via MarketMinute
Topics Economy Government Supply Chain
Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings. 
Via Benzinga
3 Big Dividend Plays With Strong Earnings to Back Them
Three major dividend names—Waste Management, Eversource, and Johnson & Johnson—each gave investors new reasons to keep them in mind thanks to recent earnings. 
Via MarketBeat
Topics Earnings
Worried About a Fading Rally? Consider These 3 Dividend Stocks
Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income. 
Via MarketBeat
Topics Artificial Intelligence Economy
5 Dividend Stocks to Hold for the Next 5 Years
These top dividend stocks should deliver strong total returns over the next half-decade. 
Via The Motley Fool
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck. 
Via The Motley Fool
Topics Economy Retirement
Is the Vanguard Value ETF the Simplest Way to Consistently Collect More Passive Income Than the S&P 500?
This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends. 
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
U.S. Labor Market Shows Mixed Signals: Unemployment Claims Tick Up, Job Growth Slows
Recent economic data from the United States has presented a nuanced picture of the nation's labor market, with a slight uptick in unemployment benefit applications alongside a significantly... 
Via MarketMinute
Topics Bonds Economy
Political Tremors Rattle Markets: The Profound Impact of U.S. Elections and Tariff Shocks
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on... 
Via MarketMinute
Topics Economy Government Stocks
U.S. Economy Navigates Choppy Waters: Weak Payrolls, Labor Slowdown, and Persistent Inflation Reshape Market Outlook
The United States economy is currently grappling with a complex and often contradictory narrative, marked by recent weak payrolls data, a discernible slowdown in the labor market, and persistent... 
Via MarketMinute
Topics Earnings Economy World Trade
Stagflation Fears Resurface: Economic Data Signals Market Caution
A troubling confluence of recent economic data points has sent a shiver through financial markets, reigniting fears of "stagflation"—a dreaded economic scenario characterized by stagnant growth, high... 
Via MarketMinute
Topics Bonds Economy Government
Stagflation Specter Haunts Markets as Economic Data Disappoints
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of... 
Via MarketMinute
Topics Economy Stocks World Trade
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.